BioNTech SE (BNTX)
BioNTech's cancer drug meets primary endpoint in Phase 2 trial
Reuters
Tue, Jul 30, 2024, 1:52 PM GMT+3
To confirm the signal, we need to close 3 sessions above 87.70$
Reuters
Tue, Jul 30, 2024, 1:52 PM GMT+3
To confirm the signal, we need to close 3 sessions above 87.70$
免責聲明
這些資訊和出版物並不意味著也不構成TradingView提供或認可的金融、投資、交易或其他類型的意見或建議。請在使用條款閱讀更多資訊。